# SBIR Topic 131: Development of Bacteriophage for Treatment of Mycobacterial Infections

> **NIH NIH N43** · CFD RESEARCH CORPORATION · 2024 · $297,740

## Abstract

To provide support for preclinical research and development of therapeutic phage products that target mycobacteria. Within this scope, special emphasis is placed on preclinical development of NTM infections; and including antibiotic-resistant mycobacterial infections.

## Key facts

- **NIH application ID:** 11203283
- **Project number:** 75N93024C00060-0-9999-1
- **Recipient organization:** CFD RESEARCH CORPORATION
- **Principal Investigator:** KETAN BHATT
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $297,740
- **Award type:** —
- **Project period:** 2024-09-10 → 2025-09-09

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11203283

## Citation

> US National Institutes of Health, RePORTER application 11203283, SBIR Topic 131: Development of Bacteriophage for Treatment of Mycobacterial Infections (75N93024C00060-0-9999-1). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/11203283. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*